Company: HCWB
Filing Date: 2025-04-01
Form Type: 8-K
Source: 0000950170-25-048586
Chunk: 1

Company: HCW Biologics Inc.
Filing Date: 2025-04-01
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01 Other Events.

As disclosed above, at the Special Meeting, the stockholders of the Company approved a reverse stock split of all outstanding shares of the Common Stock, at an aggregate range from one-for-twenty (1:20) up to one-for-fifty (1:50), or anywhere between, all as determined in the sole discretion of the Board. On March 31, 2025, the Board approved a reverse stock split of the Common Stock at a final ratio of one-for-forty (1:40) (the “ Reverse Stock Split”). The Reverse Stock Split is expected to become effective at 12:01 a. m. Eastern Time on April 11, 2025, following the filing of a Certificate of Amendment of Certificate of Incorporation and a Certificate of Correction thereto with the Secretary of State of the State of Delaware. The Common Stock is expected to commence trading on a reverse split-adjusted basis when the markets open on April 11, 2025, under the existing trading symbol “ HCWB.” The new CUSIP number for the Common Stock following the Reverse Stock Split will be 40423R204.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                         HCW BIOLOGICS INC.                                 
  Date:      April 1, 2025      By:      /s/ Hing C. Wong                                   
                                         Hing C. Wong, Founder and Chief Executive Officer